p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma.

Abstract

BACKGROUND & AIMS:

p53 mutations occur frequently in human HCC. Activation of the mammalian target of rapamycin (mTOR) pathway is also associated with HCC. However, it is still unknown whether these changes together initiate HCC and can be targeted as a potential therapeutic strategy.

METHODS:

We generated mouse models in which mTOR was hyperactivated by loss of tuberous sclerosis complex 1 (Tsc1) with or without p53 haplodeficiency. Primary cells were isolated from mouse livers. Oncogenic signalling was assessed in vitro and in vivo, with or without targeted inhibition of a single molecule or multiple molecules. Transcriptional profiling was used to identify biomarkers predictive of HCC. Human HCC materials were used to corroborate the findings from mouse models.

RESULTS:

p53 haploinsufficiency facilitates mTOR signalling via the PTEN/PI3K/Akt axis, promoting HCC tumorigenesis and lung metastasis. Inhibition of PI3K/Akt reduced mTOR activity, which effectively enhanced the anticancer effort of an mTOR inhibitor. ATP-binding cassette subfamily C member 4 (Abcc4) was found to be responsible for p53 haploinsufficiency- and Tsc1 loss-driven HCC tumorigenesis. Moreover, in clinical HCC samples, Abcc4 was specifically identified an aggressive subtype. The mTOR inhibitor rapamycin significantly reduced hepatocarcinogenesis triggered by Tsc1 loss and p53 haploinsufficiency in vivo, as well as the biomarker Abcc4.

CONCLUSIONS:

Our data advance the current understanding of the activation of the PTEN/PI3K/Akt/mTOR axis and its downstream target Abcc4 in hepatocarcinogenesis driven by p53 reduction and Tsc1 loss. Targeting mTOR, an unexpected vulnerability in p53 (haplo)deficiency HCC, can be exploited therapeutically to treat Abcc4-positive patients with HCC.

LAY SUMMARY:

Tsc1 loss facilitates the p53 (haplo)insufficiency-mediated activation of the PTEN/Akt/mTOR axis, leading to the elevated expression of Abcc4 to drive HCC tumorigenesis and metastasis in mice. Inhibition of mTOR protects against p53 haploinsufficiency and Tsc1 loss-triggered tumour-promoting activity, providing a new approach for treating an aggressive subtype of HCC exhibiting high Abcc4 expression.

• Authors: Yuan-Deng Luo, Lei Fang, Hong-Qiang Yu, Jie Zhang, Xiao-Tong Lin, Xiao-Yu Liu, Di Wu, Gui-Xi Li, Deng Huang, Yu-Jun Zhang, Shu Chen, Yan Jiang, Ling Shuai, Yu He, Lei-Da Zhang, Ping Bie, Chuan-Ming Xie
• Journal: Journal of hepatology (J Hepatol) Vol. 74 Issue 1 Pg. 96-108 (01 2021) ISSN: 1600-0641 [Electronic] Netherlands
• PMID: 32738450 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Chemical References

• Abcc4 protein, mouse
• Biomarkers, Tumor
• MTOR Inhibitors
• Multidrug Resistance-Associated Proteins
• Pyrazoles
• Pyrimidines
• Trp53 protein, mouse
• Tsc1 protein, mouse
• Tuberous Sclerosis Complex 1 Protein
• Tumor Suppressor Protein p53
• mTOR protein, mouse
• TOR Serine-Threonine Kinases
• sapanisertib
• Sirolimus

Topics

• Animals
• Biomarkers, Tumor (genetics)
• Carcinoma, Hepatocellular (drug therapy, genetics, metabolism)
• Gene Expression Regulation, Neoplastic (drug effects)
• Haploinsufficiency (drug effects, genetics)
• Humans
• Liver Neoplasms (drug therapy, genetics, metabolism)
• MTOR Inhibitors (pharmacology)
• Mice
• Multidrug Resistance-Associated Proteins (genetics)
• Pyrazoles (pharmacology)
• Pyrimidines (pharmacology)
• Signal Transduction (drug effects)
• Sirolimus (pharmacology)
• TOR Serine-Threonine Kinases (genetics)
• Tuberous Sclerosis Complex 1 Protein (genetics)
• Tumor Suppressor Protein p53 (genetics)